Small-molecule kinase inhibitors: an analysis of FDA-approved drugs.
about
Delineation of Polypharmacology across the Human Structural Kinome Using a Functional Site Interaction Fingerprint ApproachCirculating and disseminated tumor cells: diagnostic tools and therapeutic targets in motionThe Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network PerspectiveHigh quality, small molecule-activity datasets for kinase researchChemical Proteomic Profiling of Human MethyltransferasesTargeting kinase signaling pathways with constrained peptide scaffolds.Insights into the binding mode of MEK type-III inhibitors. A step towards discovering and designing allosteric kinase inhibitors across the human kinomeA metal-catalyzed enyne-cyclization step for the synthesis of bi- and tricyclic scaffolds amenable to molecular library production.High-content screen using zebrafish (Danio rerio) embryos identifies a novel kinase activator and inhibitor.BIRC6 mediates imatinib resistance independently of Mcl-1.The Role of Adaptive Immunity in the Efficacy of Targeted Cancer TherapiesA novel protein kinase is essential in bloodstream Trypanosoma bruceiAntiangiogenic cancer treatment: The great discovery and greater complexity (Review).Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluationSex-Divergent Clinical Outcomes and Precision Medicine: An Important New Role for Institutional Review Boards and Research Ethics Committees.Dual abrogation of MNK and mTOR: a novel therapeutic approach for the treatment of aggressive cancers.Surface tuning laser desorption/ionization mass spectrometry (STLDI-MS) for the analysis of small molecules using quantum dots.Design, Synthesis and Anti-Proliferative Activities of 2,6-Substituted Thieno[3,2-d]pyrimidine Derivatives Containing Electrophilic Warheads.Design, synthesis, and biological evaluation of pyrimidine derivatives as potential inhibitors of human calcium/calmodulin-dependent protein kinase IV.Kinase targets in CNS drug discovery.Photoactivatable Caged Prodrugs of VEGFR-2 Kinase Inhibitors.Targeting a Targeted Drug: An Approach Toward Hypoxia-Activatable Tyrosine Kinase Inhibitor Prodrugs.Targeting the Breast Cancer Kinome.Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas.Impact of phosphoproteomics in the translation of kinase-targeted therapies.Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).HPLC-UV method for simultaneous determination of MK-1775 and AZD-7762 in both acetonitrile-aqueous solution and mouse plasma.Hyperglycaemia Induced by Novel Anticancer Agents: An Undesirable Complication or a Potential Therapeutic Opportunity?From Type I to Type II: Design, Synthesis, and Characterization of Potent Pyrazin-2-ones as DFG-Out Inhibitors of PDGFRβ.Non-kinase targets of protein kinase inhibitors.Advances of small molecule targeting of kinases.Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates.Conquering the challenges of genotypic and phenotypic tumor heterogeneity to realize the promise of personalized cancer therapy: the role of academia.Mechanistic Systems Modeling to Improve Understanding and Prediction of Cardiotoxicity Caused by Targeted Cancer Therapeutics.Effect of Narrow Spectrum Versus Selective Kinase Inhibitors on the Intestinal Proinflammatory Immune Response in Ulcerative ColitisComparison of FDA Approved Kinase Targets to Clinical Trial Ones: Insights from Their System Profiles and Drug-Target Interaction Networks.Identification of genes highly downregulated in pancreatic cancer through a meta-analysis of microarray datasets: implications for discovery of novel tumor-suppressor genes and therapeutic targets.Marine-Derived 2-Aminoimidazolone Alkaloids. Leucettamine B-Related Polyandrocarpamines Inhibit Mammalian and Protozoan DYRK & CLK Kinases.Design, Synthesis, and Biological Evaluation of Novel 1,3,4-Thiadiazole Derivatives as Potential Antitumor Agents against Chronic Myelogenous Leukemia: Striking Effect of Nitrothiazole Moiety.
P2860
Q24672143-B91472CC-1022-4D26-8F61-26C4B8849513Q28066285-C0C66AE1-C00E-4E3B-9C57-F4D92E06E6E3Q28553277-43A701A6-3AA2-4871-82A4-8071883B4F64Q28596330-3D1F10E2-3B7C-4131-87F5-B15809FC89CAQ28821490-687D9EC6-5034-4681-8BB4-299FE585337CQ30398451-4627A336-488D-45E7-8768-F37AF2F78C93Q33811883-ADF12F56-A018-4D33-A287-AFA055C474B6Q36064161-353EA7F5-0396-43BE-860C-6EECF49EDA12Q36315532-068DFFE0-A703-407C-9D53-21915E480106Q36375641-128E6F43-B947-4962-B522-6308B104EB40Q36535465-BBB69E2F-EDB6-49BA-ACAE-89FDDD7C84BBQ37047925-98AF278E-91E7-4757-A273-34C03AD43A49Q37337814-885A7535-6903-443E-AE3B-E0D1A9E4AAABQ37699220-CD61734E-0B5A-48D1-8CB3-F65386DB0FB9Q38635940-16E032C0-6FC7-4539-B37B-E7EF18417266Q38637354-FED996A2-3489-44DC-9FD3-A83FDF9E97AFQ38661181-D0D78C0A-9CE2-4556-956F-6F5546CF6C96Q38703752-147A2151-C961-4FB1-B845-0280E9EEF618Q38733703-40AB692A-C9C1-4A5C-BF69-DBE038961AF0Q38760031-03E18830-AD46-46E8-905E-E55D07D39A76Q38773791-26006247-E2AF-41B3-809E-77F8C2CBE90EQ38814550-C1FF69D1-470F-479B-A477-95CFE4C3D114Q38836110-33DC6BA2-6EF5-462F-A97F-31574FDD2DC9Q38922319-319B38E9-6836-4FD3-8AF2-0A6C41A5F855Q38930166-3F503493-D9EA-4160-9610-751789EAEE5BQ38989188-8B7E72DE-FBD9-4C50-8918-1DC91CE4BF68Q39003757-90787108-4AF3-4D05-99D4-DF186C5ADA4FQ39020753-BC93D5E5-FE80-496A-A828-88399E16A5B2Q39040854-379239ED-B4FB-44C0-A55B-BDC5A3BF2F44Q39154885-C3BB611B-45DA-4572-B969-BBEBC1C7829BQ39171961-1595C70C-A575-49FD-8A66-C8DE84883691Q39450797-976E11D0-8F52-4239-AA3B-37FA581D46FFQ41039819-0FDC70F8-DA62-442E-B4B9-532D8EA0DEB1Q41112169-0DF2264F-5C63-4F80-9AAF-7C24DC294E0BQ41688591-D894A5C2-9EA6-44F1-B3F9-0B87146F014DQ41826640-1A19F1C8-F1F7-4FB4-87DF-16A3F9E07A96Q42195551-DCDBBA09-3BA9-4011-836A-6E11A290C9CAQ47243883-529D3372-5AFE-49DF-8FAD-F950478D9558Q47250488-45FFC5AF-377E-4CB5-8EFA-183E8C47C671Q47252106-D1E54AB8-29B0-4720-96A8-B1C5EB46AEBD
P2860
Small-molecule kinase inhibitors: an analysis of FDA-approved drugs.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Small-molecule kinase inhibitors: an analysis of FDA-approved drugs.
@en
Small-molecule kinase inhibitors: an analysis of FDA-approved drugs.
@nl
type
label
Small-molecule kinase inhibitors: an analysis of FDA-approved drugs.
@en
Small-molecule kinase inhibitors: an analysis of FDA-approved drugs.
@nl
prefLabel
Small-molecule kinase inhibitors: an analysis of FDA-approved drugs.
@en
Small-molecule kinase inhibitors: an analysis of FDA-approved drugs.
@nl
P1433
P1476
Small-molecule kinase inhibitors: an analysis of FDA-approved drugs
@en
P2093
Thomas E Nielsen
P356
10.1016/J.DRUDIS.2015.07.008
P577
2015-07-23T00:00:00Z